N@N

REGN, EGLE, VG, SSS, DSCO, SRDX Expected To Be Lower After Earnings Releases on Wednesday

^{Published on 2009-10-31 11:34:45, Last Modified on 2010-12-22 17:28:13 - WOPRAI}
 

November 2, 2009 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Wednesday, November 4th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and November earnings reports. Regeneron Pharmaceuticals (NASDAQ: REGN), Eagle Bulk Shipping (NASDAQ: EGLE), Vonage Holdings (NYSE: VG), Sovran Self Storage (NYSE: SSS), Discovery Laboratories (NASDAQ: DSCO) and SurModics (NASDAQ: SRDX) are all expected to be lower after their earnings are released Wednesday. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go lower after earnings are released Wednesday:

Symbol Company # of Reports Quarter Release Time

REGN Regeneron Pharmaceut November earnings Q3 Before

EGLE Eagle Bulk Shipping 12 quarters Q3 After

VG Vonage Holdings Corp. 12 quarters Q3 Before

SSS Sovran Self Storage 12 quarters Q3 After

DSCO Discovery Laboratories 12 quarters Q3 Before

SRDX SurModics, Inc. 12 quarters Q4 After

Earnings, or profits, drive stock prices. The market values a company based on its current and anticipated future ability to make money. The market takes the earnings pulse of a company four times per year when quarterly reports are issued. When this information is released it can often be a trend-changing or a trend confirming event because the information is so vital to the market's perception of the vitality of that company.

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN), an integrated biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The companya�s commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical trials include Aflibercept for the treatment of oncology; VEGF Trap-Eye in wet AMD in patients for eye diseases; and ARCALYST versus placebo for the prevention of gout flares in patients initiating urate-lowering drug therapy. The companya�s products under clinical trials include REGN88, an antibody to the Interleukin-6 receptor (IL-6R) that is being evaluated in patients with rheumatoid arthritis; REGN421, an antibody to delta-like ligand-4 that is being developed for oncology; and REGN475, an antibody to nerve growth factor, which is being developed for the treatment of pain. Regeneron Pharmaceuticals also conducts other preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, and cardiovascular diseases. The company has strategic collaboration agreements with sanofi-aventis Group to discover, develop, and commercialize fully human monoclonal antibodies; and Bayer HealthCare LLC for the development of the VEGF-Trap-Eye. Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York.

Eagle Bulk Shipping Inc. (NASDAQ: EGLE) engages in the ocean transportation of bulk cargoes in the dry bulk industry. The company transports primarily iron ore, coal, grain, cement, and fertilizer along worldwide shipping routes. As of December 31, 2008, it owned and operated a fleet of 23 oceangoing vessels with a combined carrying capacity of 1,184,939 deadweight tons. The company was founded in 2005 and is headquartered in New York, New York.

Vonage Holdings Corp. (NYSE: VG), through its subsidiaries, provides broadband Voice over Internet Protocol services to residential and small business and home office customers. It offers various features, such as call waiting, caller ID with name, call forwarding, and voicemail. The company also provides area code selection, number portability, online account management, and personalized Web-enabled voicemail. In addition, it offers services, including Vonage visual voicemails, virtual phone numbers, toll free numbers, and residential and business fax services, as well as Vonage SoftPhone, a software application that is downloaded and installed on computers, laptops, and WiFi-enabled personal digital assistant devices, which enables user to use a computer as a telephone. Further, the company offers Vonage-enabled devices, such as Vonage V-Portal to connect up to two Vonage lines through a high-speed Internet connection and includes a networking router; analog telephone adapters, which convert analog audio signals into digital data packets for transmission over the Internet; integrated adapters and wireless routers; Vonage Bundled Cordless Phone; V-phone, a USB compatible device; and Vonage Companion, a downloadable softphone that can be loaded on a laptop or PC. As of December 31, 2008, it had approximately 2.6 million subscriber lines in service. The company was incorporated in 2000 and is headquartered in Holmdel, New Jersey.

Sovran Self Storage, Inc. (NYSE: SSS) operates as a real estate investment trust (REIT). It engages in the acquisition, ownership, and management of self-storage properties in the United States. The companya�s self-storage properties offer storage space to residential and commercial users, as well as offer outside storage for automobiles, recreational vehicles, and boats. As of February 15, 2007, it owned and managed 328 properties, consisting of approximately 20.3 million net rentable square feet in 22 states. Sovran Self Storage has elected to be treated as a REIT for federal income tax purposes and would not be subject to income tax to the extent it distributes at least 90% of taxable income to its stockholders. The company was founded in 1982 and is headquartered in Williamsville, New York.

Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The companya�s proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania.

SurModics, Inc. (NASDAQ: SRDX) engages in the development, manufacture, and sale of surface modification and drug delivery technologies to the healthcare industry. The company operates in three segments: Drug Delivery, Hydrophilic and Other, and In Vitro. The Drug Delivery segment contains the Drug Delivery business unit, which offers technologies to site-specific delivery of drugs; the Ophthalmology business unit that provides treatment for eye diseases, such as age-related macular degeneration and diabetic macular edema; and the Brookwood Pharmaceuticals unit, which offers proprietary polymer-based technologies. The Hydrophilic and Other segment consists of three business units comprising the Hydrophilic Technologies business unit, which focuses on enhancing medical devices with lubricious coatings that facilitate their placement and maneuverability in the body; the Regenerative Technologies business unit that develops platforms to augment or replace tissue/organ function, or to modify medical devices to facilitate tissue/organ recovery through natural repair mechanisms; and the Orthopedics business unit, which provides solutions for orthopedics patients using proven surmodics technologies, and creates new technology solutions to existing patient care gaps in the orthopedics field. The In Vitro segment contains the In Vitro Technologies business unit, which offers microarray slide technologies, stabilization products, antigens, and substrates for immunoassay diagnostics tests, in vitro diagnostic format technology, and synthetic ECM cell culture products. The company markets its technologies and products in the United States and internationally. It has collaboration agreements with Donaldson Company, Inc. for the development of synthetic ECM cell culture products; and Merck & Co., Inc. for development and commercialization of products incorporating the companya�s I-vation platform. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641